What Researchers Did
Researchers examined hematological safety of HBOT in 259 Korean oncology patients, tracking blood count changes before and after treatment courses.
What They Found
HBOT did not cause clinically significant changes in hemoglobin, white blood cell count, or platelet levels in oncology patients. The therapy was considered hematologically safe across the study population.
What This Means for Canadian Patients
Many Canadian cancer patients are concerned about how HBOT might interact with their compromised blood counts during or after treatment. This study provides reassurance that HBOT does not meaningfully worsen hematological status in this population.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
Retrospective design and single-country data may limit generalizability to all cancer types and treatment regimens.